PMID

Data

Article Title

Organization

PD 176252--the first high affinity non-peptide gastrin-releasing peptide (BB2) receptor antagonist.

Cambridge University Forvie Site

 

Design and synthesis of a targeted set of aromatic amino acid derivatives for identification of new lead compounds

TBA

 

PD 165929 the first high affinity non-peptide neuromedin-B (NMB) receptor selective antagonist

TBA

Discovery of MK-5046, a Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity

TBA

Synthesis and SAR of derivatives based on 2-biarylethylimidazole as bombesin receptor subtype-3 (BRS-3) agonists for the treatment of obesity.

Merck Research Laboratories

Discovery of substituted biphenyl imidazoles as potent, bioavailable bombesin receptor subtype-3 agonists.

Merck Research Laboratories

Discovery and optimization of a novel Neuromedin B receptor antagonist.

Amgen

Discovery of small molecule agonists for the bombesin receptor subtype 3 (BRS-3) based on an omeprazole lead.

Glaxosmithkline

Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study.

National Center For Scientific Research Demokritos

Identification and optimization of novel partial agonists of neuromedin B receptor using parallel synthesis.

Tularik

Design of selective peptidomimetic agonists for the human orphan receptor BRS-3.

Technische UniversitäT MüNchen

Synthesis, Biological Evaluation, and Molecular Docking of 8-imino-2-oxo-2H,8H-pyrano[2,3-f]chromene Analogs: New Dual AChE Inhibitors as Potential Drugs for the Treatment of Alzheimer's Disease.

Yogi Vemana University

Arylazolyl(azinyl)thioacetanilides: Part 19: Discovery of Novel Substituted Imidazo[4,5-b]pyridin-2-ylthioacetanilides as Potent HIV NNRTIs Via a Structure-based Bioisosterism Approach.

Shandong University